Method and compositions for improving allogeneic hematopoietic cell transplantation

A hematopoietic system and cell technology, which is applied in the pharmaceutical application field of homologous hematopoietic system reconstituted cells

Inactive Publication Date: 2005-08-03
EMORY UNIVERSITY
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, even with this management, such patients still require GvHD prophylaxis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0061] Example 1. Transplant Patient Checkup

[0062] The investigation of allografts or allografts was characterized in that it was performed on 104 patients who had received non-T cell depleted allogeneic bone marrow transplants from HLA-matched siblings. Pretransplant status adjustments for these patients included butyl dimesylate treatment (n=89), total body irradiation with administration of cyclophosphamide (n=10), and cyclophosphamide (n=5). The total number of cells in the graft averaged 3 × 10 8 Cells / kg recipient body weight. CD34 + The number of cells correlated positively with an increase in survival (p=0.0004, overall survival; p=0.001, disease-free survival). The graft was additionally quantified for a cell population characterized by CD3 - , CD4 +(Hi) , CD8 - , low side scatter, here considered DCP, the number of these cells in transplanted species was inversely correlated with overall survival (OS) and disease-free survival (DFS, p=0.005). In this surv...

Embodiment 2

[0064] Example 2. Transplantation of selected stem cells

[0065] donor source : Bone marrow or peripheral blood stem cells collected from HLA-matched or mismatched donors.

[0066] Donor PBSC collection : To immobilize PBSC, G-CSF was administered daily until complete depletion of leukocytes. Donors received subcutaneous injections of G-CSF at 10 μg / kg / day according to their actual body weight. Institutional standards of donor support care must be followed during mobilization and leukapheresis. PBSC were collected by leukapheresis. Leukocyte depletion should be performed on a continuous flow cytometry instrument according to institutional standard methods. The endpoint of each leukapheresis collection should be the processing of more than 12 liters of whole blood or 4 hours of leukapheresis. Leukapheresis should be done after donor G-CSF treatment + Start on day 5 and proceed daily (leukapheresis up to four days) until 2 x 10 6 CD34 + Target cells / kg recipient bo...

Embodiment 3

[0070] Example 3. cell sorting

[0071] General protocol for cell sorting. Cells were stained with FITC-conjugated CD34-specific monoclonal antibodies and PE-conjugated monoclonal antibodies recognizing CD4, CD123, CD36 or CD45RA (Becton-Dickinson, San Jose, CA). A directly conjugated isotype-matched irrelevant antibody was used as a reference. Cells were stained for 30 min at 4°C in a staining buffer consisting of Hank's saline buffered solution (HBSS, Mediatech, Herndon, VA) containing 2% v / v autologous human plasma or 1% human serum albumin. Excess antibody was removed by dilution with 10 volumes of staining buffer followed by centrifugation at 500 xg. Stained cells were analyzed indirectly using a FACSCAN flow cytometer (BDIS, San Jose, CA) or sorted aseptically using a FACSVANTAGE cell sorter (BDIS, San Jose, CA). Central and marginal scatter gates for viable nucleated cells were used to obtain list-mode data. Using CellQuest TM Or LYSIS-II software (BDIS, San Jos...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Methods of reducing or preventing graft versus host disease in an allogeneic hematopoietic system reconstituting cells transplant recipient comprising administering to the recipient allogeneic hematopoietic system reconstituting cells in which the number of dendritic cells has been effectively reduced, thereby reducing or preventing graft versus host disease, are provided. Also provided are methods of increasing the chance of survival for an allogeneic hematopoietic system reconstituting cells transplant recipient comprising administering to the recipient allogeneic hematopoietic system reconstituting cells in which the number of dendritic cells has been effectively reduced, thereby improving the chance for survival of the recipient. Columns for preparing hematopoietic system reconstituting cells prior to their transplantation are disclosed that provide for the selection of CD34+ cells and the removal of dendritic cell progenitors.

Description

Field of the invention [0001] The field of the invention is improved methods of transplanting allogeneic hematopoietic reconstituted cells from a donor into genetically distinct recipients, and the field also relates to the depletion of specific hematopoietic cell types, which are removed The presence of is associated with decreased survival of transplant recipients. Background of the invention [0002] Allogeneic bone marrow transplantation is the preferred method of treatment for a variety of malignant and inherited blood and hematopoietic cell disorders. Widespread use of this therapy is limited by the availability of suitable bone marrow donors who are genetically related to the patient and have the same transplant antigens on the surface of blood cells. Only 25% of patients had a potential donor whose sibling was an antigen match. Patients lacking an appropriate sibling donor can be treated by using bone marrow from an antigenically matched but genetically unrelated d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C12M1/00A61K35/12A61K35/14A61K35/28A61P7/00A61P43/00C12N5/00C12N5/06C12R1/91
CPCA61K2035/124C12N5/0087A61P43/00A61P7/00A61K35/28
Inventor E·K·瓦勒
Owner EMORY UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap